SEC Comment Letter for Propanc Biopharma, Inc. (PPCB) (CIK 0001517681) (PPCB) — Mar 5, 2019
Propanc Biopharma, Inc. (PPCB) (CIK 0001517681)
Date: March 5, 2019 · CIK: 0001517681 · Accession: 0000000000-19-003842
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229856
Letter
March 5, 2019 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC, 3124 Australia Re:Propanc Biopharma, Inc. Registration Statement on Form S-1 Filed February 25, 2019 File No. 333-229856 Dear Mr. Nathanielsz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tonya K. Aldave at (202) 551-3601 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Sasha Ablovatskiy, Esq.
Show Raw Text
March 5, 2019
James Nathanielsz
Chief Executive Officer
Propanc Biopharma, Inc.
302, 6 Butler Street
Camberwell, VIC, 3124 Australia
Re:Propanc Biopharma, Inc.
Registration Statement on Form S-1
Filed February 25, 2019
File No. 333-229856
Dear Mr. Nathanielsz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tonya K. Aldave at (202) 551-3601 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Sasha Ablovatskiy, Esq.